Epoch Biotech Highlights New Preclinical Data for APOE Christchurch-Mimetic Antibody at AAIC 2026 Demonstrating Favorable PK/PD and Differentiated Biomarker Approach
7C11 antibody builds on APOE Christchurch variant biology associated with resilience to Alzheimer’s disease, including effects on tau, amyloid and the brain vasculature New non-human primate data…
Read the full articleYou might also wanna read
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volun
Roche Aktie: Neue Alzheimer-Daten im Juli
Roche geht einen ungewöhnlichen Weg in der Alzheimer-Forschung. Der Schweizer Pharmakonzern verknüpft seine Diagnostik-Sparte mit der Entwic
https://doi.org/10.1126/science.aeb6987
Blood biomarker pinpoints when Alzheimer's shift from amyloid to tau occurs—with precision, improving early intervention prospects. PMID:420
Study Finds Variability in Performance of FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio Test for Alzheimer Disease
This cross-sectional study evaluates the performance of the US Food and Drug Administration–cleared phosphorylated tau 217 (p-tau217) to β-a
doi.org·14d agoAC Immune Aktie: AAIC in London im Fokus
AC Immune steht vor einer richtungsweisenden Woche. Der Biotech-Sektor blickt gespannt auf den kommenden Alzheimer-Weltkongress AAIC in Lond
Well-characterized biospecimens assist development of cancer immunotherapies
AMSBIO (Oxford, UK) reports how its biospecimens were used in a large-scale immuno-oncology study analyzing fibroblast activation protein (F
Comments
Sign in to join the conversation.
No comments yet. Be the first.